Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Next Previous
Trial Profile

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Interstitial lung diseases; Pulmonary fibrosis
  • Focus Adverse reactions; Registrational
  • Acronyms INBUILD-ON; Nintedanib in PF-ILD (extension)
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 09 Jan 2025 Results assessing the safety of nintedanib during longer-term treatment published in the Lung.
  • 15 Nov 2023 Results assessing data from patients with progressive pulmonary fibrosis related to autoimmune disease, presented at the ACR Convergence 2023.
  • 14 Nov 2022 Results assessing the adverse events and changes in FVC in INBUILD-ON in patients with autoimmune disease-related ILDs based on a data snapshot taken on 15 October 2021 from the subgroup of patients (n=434) with progressive pulmonary fibrosis, presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top